These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 38071059

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study.
    Chu B, Wang YT, Gao S, Shi L, Lu MQ, Fang LJ, Xiang QQ, Chen Y, Wang MZ, Wang LF, Sun K, Yang J, Duan F, Bao L.
    Ann Hematol; 2024 Sep; 103(9):3677-3690. PubMed ID: 38955826
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J, Ma J, Chen B.
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
    Jin X, Jiang X, Li H, Shen K, Liu S, Chen M, Yang C, Han B, Zhuang J.
    Acta Haematol; 2024 Apr 16; ():1-10. PubMed ID: 38626745
    [Abstract] [Full Text] [Related]

  • 6. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.
    Han W, Jin Y, Xu M, Zhao SS, Shi Q, Qu X, Zhang R, Li J, Wu Y, Chen L.
    Hematology; 2021 Dec 16; 26(1):510-517. PubMed ID: 34314294
    [Abstract] [Full Text] [Related]

  • 7. Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.
    Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K.
    Eur J Nucl Med Mol Imaging; 2019 Jun 16; 46(6):1325-1333. PubMed ID: 30687892
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.
    Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM, Teixidó M, Gimenez MT, Senín A, Sanz P, Campoy D, Vicent A, Arenillas L, Rosiñol L, Sierra J, Bladé J, de Larrea CF, GEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya).
    Haematologica; 2017 Jun 16; 102(6):1099-1104. PubMed ID: 28255016
    [Abstract] [Full Text] [Related]

  • 9. [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].
    Deng JJ, Jin XY, Zhang ZY, Zhou HX, Yang GZ, Geng CY, Jian Y, Chen WM, Gao W.
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul 14; 45(7):645-650. PubMed ID: 39231768
    [Abstract] [Full Text] [Related]

  • 10. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
    van de Donk NWCJ.
    J Clin Oncol; 2023 Mar 01; 41(7):1342-1349. PubMed ID: 36450104
    [Abstract] [Full Text] [Related]

  • 11. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ, Wang FR, Wen L, Chen Y, Chen H, Huang XJ, Lu J.
    Zhonghua Nei Ke Za Zhi; 2020 Oct 01; 59(10):801-806. PubMed ID: 32987483
    [Abstract] [Full Text] [Related]

  • 12. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.
    Cancer; 2019 Feb 01; 125(3):416-423. PubMed ID: 30332496
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
    Chen Z, Xia Y, Guo R, Zhang R, Qiu HR, Jin YY, Li JY, Chen LJ.
    Zhonghua Xue Ye Xue Za Zhi; 2022 May 14; 43(5):408-413. PubMed ID: 35680599
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H, Li JY, Sun C, Zhou X.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec 14; 25(6):1837-1841. PubMed ID: 29262927
    [Abstract] [Full Text] [Related]

  • 19. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
    Li Q, Ai L, Zuo L, Li J, Zhao F, Xu A, Zhang B, Cai L, Hu Y, Sun C.
    Ann Med; 2024 Dec 14; 56(1):2338604. PubMed ID: 38599340
    [Abstract] [Full Text] [Related]

  • 20. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
    Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Bladé J, Rajkumar SV, Mateos MV.
    Blood Cancer J; 2021 Dec 02; 11(12):192. PubMed ID: 34857730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.